Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Alzheimer's Disease

  Free Subscription


26.01.2026

1 Acta Neuropathol
19 Alzheimers Dement
2 Am J Alzheimers Dis Other Demen
1 BMC Neurol
2 Brain
1 Brain Res
1 Int J Neurosci
13 J Alzheimers Dis
1 J Biol Chem
1 J Neurol Neurosurg Psychiatry
2 J Neurosci
1 JAMA
1 Nature
1 Neurochem Res
1 Neurosci Lett
2 Neuroscience
1 PLoS Med


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neuropathol

  1. FERTAN E, Kedia S, Nolan G, Meisl G, et al
    Early synaptic pathology is associated with small tau aggregates in Alzheimer's disease.
    Acta Neuropathol. 2026;151:7.
    PubMed         Abstract available


    Alzheimers Dement

  2. WRIGHT GN, Dodds JN, Punnota RS, Vicidomini R, et al
    Biomarkers.
    Alzheimers Dement. 2025;21 Suppl 2.
    PubMed         Abstract available

  3. ROCHA A, Bellaver B, Soares C, Ferreira PCL, et al
    Biomarkers.
    Alzheimers Dement. 2025;21 Suppl 2.
    PubMed         Abstract available

  4. SALMON DP, Ede C, Gigliotti C, Little EA, et al
    A cognitive screening program in community-based medical clinics to facilitate Latino participation in Alzheimer's disease research.
    Alzheimers Dement. 2026;22:e71132.
    PubMed         Abstract available

  5. WARREN A, Wynia Z, Corr PG, Devin MF, et al
    The microbiota-gut-brain axis in mild cognitive impairment and Alzheimer's disease: a scoping review of human studies.
    Alzheimers Dement. 2026;22:e71023.
    PubMed         Abstract available

  6. LIU W, Li Y, Qin W, Wang X, et al
    The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status.
    Alzheimers Dement. 2025;21:e70193.
    PubMed         Abstract available


  7. Correction to "A blood based mitochondrial functional index biomarker for Alzheimer's disease".
    Alzheimers Dement. 2026;22:e71171.
    PubMed        

  8. WEN G, Lindblom N, Zhan X, Garcia-Ryde M, et al
    Abeta antibodies target not only amyloid plaques but also distinct brain cells and vessels.
    Alzheimers Dement. 2026;22:e71121.
    PubMed         Abstract available

  9. PINEDA-LOPEZ L, Aguillon D, Villar-Vesga J, Valderrama-Carmona P, et al
    Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71148.
    PubMed         Abstract available

  10. ARIAS JJ, Nielsen KE, Bolcic-Jankovic D, Bonham LW, et al
    Data sharing practices and experiences among Alzheimer's disease and related dementia researchers.
    Alzheimers Dement. 2026;22:e71046.
    PubMed         Abstract available

  11. MONTERO-CALLE A, Coronel R, Manosalva J, Megias D, et al
    Comprehensive profiling of Abeta40 and Abeta42 fibril-interacting proteins reveals PRKCG as a drug-targetable regulator of amyloidogenesis in Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71090.
    PubMed         Abstract available

  12. ZHONG Y, Fan B, Yang X, Huang Y, et al
    Nanoplastics trigger glial-neuronal collagen signaling miscommunication to exacerbate cognitive impairment in Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71096.
    PubMed         Abstract available

  13. HIRANSUTHIKUL A, Thanapornsangsuth P, Luechaipanit W, Haethaisong T, et al
    Blood-based Alzheimer's disease biomarkers and cognitive trajectories in older people with HIV with undetectable viral loads.
    Alzheimers Dement. 2026;22:e71101.
    PubMed         Abstract available

  14. SINGH V, Rochakim N, Ferraresso F, Garg K, et al
    Aquaporin-4 and caveolin-1 as mediators of fibrinogen-driven cerebrovascular pathology in cerebral amyloid angiopathy.
    Alzheimers Dement. 2026;22:e71030.
    PubMed         Abstract available

  15. KANG S, Ye BS, Yun M, Lee YG, et al
    Effect of tau burden and Lewy pathology on neuropsychiatric symptoms in Abeta-positive individuals.
    Alzheimers Dement. 2026;22:e71116.
    PubMed         Abstract available

  16. BURNS JM, Alford S, Coppinger J, Jimenez-Mausbach M, et al
    Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers.
    Alzheimers Dement. 2026;22:e70986.
    PubMed         Abstract available

  17. CRANE PK, Li C, Cohen T, Seitz A, et al
    Cognitive data harmonization in the ADRC Network and beyond-Past, present, and future.
    Alzheimers Dement. 2026;22:e71086.
    PubMed         Abstract available

  18. KENNEDY JT, Wisch JK, Boerwinkle AH, Millar PR, et al
    Brain volume trajectories in Down syndrome and autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71103.
    PubMed         Abstract available

  19. EISSMAN JM, Ma Y, Qiao M, Reyes-Dumeyer D, et al
    Biological age acceleration associates with Alzheimer's disease plasma biomarker levels.
    Alzheimers Dement. 2026;22:e71005.
    PubMed         Abstract available

  20. KANDIMALLA M, Lim S, Jacobson DN, Lee J, et al
    Neuroinflammation demonstrated by (11)C-ER176 PET with amyloid and tau pathology.
    Alzheimers Dement. 2026;22:e71027.
    PubMed         Abstract available


    Am J Alzheimers Dis Other Demen

  21. MASOOD F, Al-Hyari A, Al-Wajidi W
    Comparison Study of Different Feature Selection Techniques for the Diagnosis of Alzheimer's Disease.
    Am J Alzheimers Dis Other Demen. 2026;41:15333175261418472.
    PubMed         Abstract available

  22. BROWN SE, Bowen ZJ, Rosati Yoos LL, Sakthi-Velavan S, et al
    A Unique Case of Post-Subarachnoid Hemorrhage Cerebral Atrophy and Its Implications on Alzheimer's Disease.
    Am J Alzheimers Dis Other Demen. 2026;41:15333175261420559.
    PubMed         Abstract available


    BMC Neurol

  23. LOBO JD, Serrano VB, Campbell LM, Bell T, et al
    Cerebrospinal fluid markers of alzheimer's pathology relate to aMCI among people with HIV.
    BMC Neurol. 2026 Jan 17. doi: 10.1186/s12883-025-04585.
    PubMed        


    Brain

  24. TRUDEL L, Therriault J, Macedo AC, Hosseini SA, et al
    Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.
    Brain. 2026 Jan 20:awag018. doi: 10.1093.
    PubMed         Abstract available

  25. MEHTA RI, Wang T, Leurgans SE, Bennett DA, et al
    Cerebral amyloid angiopathy and Alzheimer's and related pathologies across APOE genotypes.
    Brain. 2026 Jan 22:awag025. doi: 10.1093.
    PubMed         Abstract available


    Brain Res

  26. CORIA-LUCERO C, Lopez M, Gomez-Mejiba S, Ramirez D, et al
    Daily temporal organization of inflammation and cognition-related factors and antioxidant enzymes are modified by an intracerebroventricular injection of amyloid-beta peptide (1-42) aggregates in the rat temporal cortex.
    Brain Res. 2026;1874:150135.
    PubMed         Abstract available


    Int J Neurosci

  27. ZHU L, Pan Y, Wang ZL
    Graph-Theoretical Analysis of Resting-State EEG Networks Differentiates Alzheimer's Disease and Frontotemporal Dementia.
    Int J Neurosci. 2026 Jan 22:1-16. doi: 10.1080/00207454.2026.2620704.
    PubMed         Abstract available


    J Alzheimers Dis

  28. YOKOI K, Tsujimoto M, Suzuki K, Takeda A, et al
    Antiseizure therapy attenuates cognitive decline in Alzheimer's disease: A retrospective cohort study.
    J Alzheimers Dis. 2026 Jan 22:13872877251414147. doi: 10.1177/13872877251414147.
    PubMed         Abstract available

  29. PATEL PJ, Yan Z
    Epigenomic aberrations of histone methylation in prefrontal cortex of humans with mild cognitive impairment and Alzheimer's disease.
    J Alzheimers Dis. 2026 Jan 21:13872877251414887. doi: 10.1177/13872877251414887.
    PubMed         Abstract available

  30. WAN Z, Feng X, Chou J, Zhou X, et al
    Sex- and brain region-specific gene expression in Alzheimer's disease.
    J Alzheimers Dis. 2026 Jan 21:13872877251413797. doi: 10.1177/13872877251413797.
    PubMed         Abstract available

  31. CUSTODIO B, Montesinos R, Bayona W, Rojas Benites MJ, et al
    Perceptions of Peruvian neurologists toward the implementation of anti-amyloid drugs for early Alzheimer's disease in the departments of neurology.
    J Alzheimers Dis. 2026 Jan 21:13872877251410959. doi: 10.1177/13872877251410959.
    PubMed         Abstract available

  32. DALY T
    Nothing about us without us? Using public consensus for priority setting in Alzheimer's disease research.
    J Alzheimers Dis. 2026 Jan 20:13872877261415592. doi: 10.1177/13872877261415592.
    PubMed         Abstract available

  33. WANG EJ, Oguztuzun C, Xu R, Gao Z, et al
    Comparative evaluation of large language models in retrieving known and predicting novel drug combinations.
    J Alzheimers Dis. 2026 Jan 20:13872877261415635. doi: 10.1177/13872877261415635.
    PubMed         Abstract available

  34. ROTH S, Yan J, Patru MM, Mattke S, et al
    The capacity for Alzheimer's disease confirmatory testing in the United States: The current situation and simulations for future increase.
    J Alzheimers Dis. 2026 Jan 20:13872877251406909. doi: 10.1177/13872877251406909.
    PubMed         Abstract available

  35. FRANCIS L, Beiser A, Lu S, Kujawa SG, et al
    Hearing loss in the young-old is associated with increased risk for Alzheimer's disease and vascular dementia.
    J Alzheimers Dis. 2026 Jan 20:13872877251407211. doi: 10.1177/13872877251407211.
    PubMed         Abstract available

  36. ROYALL DR, Palmer RF
    Affliction class moderates the impact of neurodegeneration: Implications for A/T/N.
    J Alzheimers Dis. 2026;109:960-971.
    PubMed         Abstract available

  37. SERRA L, Bonarota S, Di Domenico C, Caruso G, et al
    Surface-based but not voxel-based morphometry reveals structural abnormalities in individuals with subjective cognitive decline.
    J Alzheimers Dis. 2026;109:781-798.
    PubMed         Abstract available

  38. RABL M, Zullo L, Wehrli J, Hossel K, et al
    Omics-AD-A multimodal biomarker study on cognitive decline and neuropsychiatric symptoms: Design and cohort characteristics.
    J Alzheimers Dis. 2026;109:889-901.
    PubMed         Abstract available

  39. ALVAREZ-PEREZ Y, Duarte-Diaz A, Molina Y, Figueroa-Lamas N, et al
    Underexplored moderating effects of sex in subjective cognitive decline: A systematic review and evidence gap.
    J Alzheimers Dis. 2026;109:604-618.
    PubMed         Abstract available

  40. AGUADO C, Alfaro-Ruiz R, Martin-Belmonte A, Puertas-Avendano R, et al
    Disruption of Ca(V)2.3 channels in the brain of the 5xFAD mice.
    J Alzheimers Dis. 2026;109:699-717.
    PubMed         Abstract available


    J Biol Chem

  41. SALVO MA, Cuddy LK, Prokopenko D, Watkins E, et al
    Alzheimer's disease-linked ACE variants increase ACE1 catalytic activity and production of angiotensin II.
    J Biol Chem. 2026 Jan 20:111171. doi: 10.1016/j.jbc.2026.111171.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  42. HU N, Yang X, Feng F, Zhang B, et al
    Amyloid-related imaging abnormalities (ARIA) in Alzheimer's immunotherapy: a framework and challenges for global surveillance strategies.
    J Neurol Neurosurg Psychiatry. 2026 Jan 22:jnnp-2025-337198.
    PubMed        


    J Neurosci

  43. LI X, Xie M, Ibanez CF
    Amelioration of symptomatic Alzheimer's Disease after selective impairment of p75(NTR) function in adult forebrain excitatory neurons.
    J Neurosci. 2026 Jan 21:e1939252026. doi: 10.1523/JNEUROSCI.1939-25.2026.
    PubMed         Abstract available

  44. MORIN TM, Cowan JL, Chen HY, Parent JH, et al
    Alzheimer's disease pathologies affect dopaminergic neural mechanisms of memory.
    J Neurosci. 2026 Jan 23:e1580252026. doi: 10.1523/JNEUROSCI.1580-25.2026.
    PubMed         Abstract available


    JAMA

  45. WHITSON HE, Fowler NR, Mielke MM
    Blood-Based Biomarkers for Alzheimer Disease: Preventing Unintended Consequences.
    JAMA. 2026 Jan 22. doi: 10.1001/jama.2025.26049.
    PubMed        


    Nature

  46. LEDFORD H
    Cancer might protect against Alzheimer's - this protein helps explain why.
    Nature. 2026 Jan 22. doi: 10.1038/d41586-026-00222.
    PubMed        


    Neurochem Res

  47. KASHIF M, Chandrabose K, Pandurangan AK
    Exploring the Therapeutic Potential of N-(3,4-dimethoxy phenyl)-6,7-dimethoxyquinazoline-4-amine (TKM01) in Aluminium-Induced Alzheimer's Disease-Like Model of Zebrafish.
    Neurochem Res. 2026;51:56.
    PubMed         Abstract available


    Neurosci Lett

  48. FUJITA Y, Yabe T, Yamada Y, Kiuchi R, et al
    MEGF10 knockout promotes cortical and hippocampal amyloid deposition in AD mouse model.
    Neurosci Lett. 2026;872:138487.
    PubMed         Abstract available


    Neuroscience

  49. QIAO J, Zhou G, Wu S, Shang H, et al
    A multi-view DTI feature fusion framework for enhanced diagnosis of Alzheimer's disease.
    Neuroscience. 2026 Jan 20:S0306-4522(26)00049.
    PubMed         Abstract available

  50. YAN L, Wang H, Shi J, Tan H, et al
    Bibliometric analysis of neuroinflammation in Alzheimer's Disease: Insights from APP/PS1 mouse model research in the past two decades.
    Neuroscience. 2026 Jan 20:S0306-4522(26)00045.
    PubMed         Abstract available


    PLoS Med

  51. ALVES F, Ayton S
    Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies.
    PLoS Med. 2026;23:e1004880.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.